News | November 24, 2021
Ipca Laboratories acquires 26 % stake in Lyka Labs, makes open offer
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Platina 250, 300 & 350 Lamitubes have been recognized by the Association of Plastic Recyclers (APR), USA as meeting or exceeding the strict APR HDPE critical guidance criteria on recyclability
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Lyka Labs has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Subscribe To Our Newsletter & Stay Updated
